🇺🇸 FDA

Company profile · Sponsor

Syndax

Syndax Pharmaceuticals Inc

SNDX · NYSE pharma NEW YORK, NY, USA
Pipeline
24
Drugs
1
Patents
6

Quick answer

Syndax (SNDX) is a pharma company. headquartered in NEW YORK, NY, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 1 drug, and 6 patents to this profile..

Company facts

Ticker SNDX
Exchange NYSE
Company type pharma
Headquarters NEW YORK, NY, USA
SEC CIK 0001395937

Pipeline (24)

Search pipeline →

  1. Revumenib

    Syndax

    Acute Myeloid Leukemias

    phase 3 small molecule active

    1 trial

  2. Revumenib, Revumenib, Placebo for Revumenib tablets, CYTARABINE, IDARUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE, Revumenib

    Syndax

    Newly Diagnosed AML with an NPM1 mutation

    phase 3 small molecule active

    1 trial

  3. AXATILIMAB

    Syndax

    Chronic graft versus host disease (cGVHD)

    phase 2 small molecule active

    1 trial

  4. AXATILIMAB, Placebo

    Syndax

    Idiopathic pulmonary fibrosis

    phase 2 small molecule active

    1 trial

  5. Atezolizumab

    Syndax

    Metastatic Cancer

    phase 2 small molecule terminated

    1 trial

  6. Axatilimab

    Syndax

    Idiopathic Pulmonary Fibrosis

    phase 2 small molecule active

    1 trial

  7. Azacitidine

    Syndax

    Non-Small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  8. Durvalumab

    Syndax

    Unresectable Intrahepatic Cholangiocarcinoma

    phase 2 small molecule completed

    1 trial

  9. Entinostat

    Syndax

    Non Small Cell Lung Cancer

    phase 2 small molecule terminated

    2 trials

  10. Entinostat

    Syndax

    Melanoma

    phase 2 small molecule completed

    1 trial

  11. Entinostat

    Syndax

    ER+ Breast Cancer

    phase 2 small molecule completed

    1 trial

  12. Entinostat

    Syndax

    Renal Cell Carcinoma

    phase 2 small molecule active

    2 trials

  13. Entinostat

    Syndax

    Hodgkin's Lymphoma

    phase 2 small molecule terminated

    1 trial

  14. Entinostat

    Syndax

    Non-Small-Cell Lung Carcinoma

    phase 2 small molecule completed

    1 trial

  15. Entinostat

    Syndax

    Lymphoma

    phase 2 small molecule active

    1 trial

  16. Entinostat

    Syndax

    Metastatic Cholangiocarcinoma

    phase 2 small molecule completed

    1 trial

  17. Fulvestrant

    Syndax

    Breast Cancer

    phase 2 small molecule terminated

    1 trial

  18. Pembrolizumab

    Syndax

    Metastatic Uveal Melanoma

    phase 2 small molecule completed

    1 trial

  19. Pembrolizumab

    Syndax

    Bladder Cancer

    phase 2 small molecule active

    1 trial

  20. Revumenib

    Syndax

    Acute Myeloid Leukemia

    phase 2 small molecule active

    2 trials

  21. Revumenib

    Syndax

    Relapsed Adult AML

    phase 2 small molecule active

    1 trial

  22. Revumenib

    Syndax

    Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  23. Revumenib

    Syndax

    Leukemia

    phase 2 small molecule active

    1 trial

  24. Revumenib, Revumenib, SNDX-5613, Revumenib, Revumenib, SNDX-5613

    Syndax

    Relapsed or Refractory Acute Leukemias

    phase 2 small molecule active

    1 trial

Drugs (1)

Search drugs →

  1. revumenib citrate

    REVUFORJ

    ORAL approved

Patents (6)

Search patents →

  1. US 12168054

    Method of treating cancer using a combination of entinostat and an anti-CSF-1R antibody

    Expires Mon Dec 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12000829

    Selection of patients for combination therapy

    Expires Mon May 30 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11919901

    Inhibitors of the menin-MLL interaction

    Expires Mon Feb 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11397184

    Selection of patients for combination therapy

    Expires Mon Jul 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11324822

    Combination of HDAC inhibitor and anti-PD-1 antibody for treatment of cancer

    Expires Mon May 05 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10226472

    Methods for the treatment of breast cancer

    Expires Mon Mar 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Syndax?

Syndax (SNDX) is a pharma company. headquartered in NEW YORK, NY, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 1 drug, and 6 patents to this profile..

What pipeline programs does Syndax sponsor?

We track 24 ClinicalTrials.gov-linked programs for Syndax, including Revumenib and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Syndax company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.